Wockhardt Ltd(WCKH.NS) faces a sharp drop in market share and delays in new launch approvals after a second plant operated by the generic drugmaker was hit by the U.S. Food and Drug Administration's "import alert", effectively a ban. An "import alert" results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices, according to the FDA website. The latest FDA action against Wockhardt's Chikalthana plant in western India, one of its key export facilities, comes amid a slew of regulatory rebukes in recent months, which has wiped off nearly three-quarters of the company's share value this year.
Help employers find you! Check out all the jobs and post your resume.
